Whipplewood Advisors LLC Makes New Investment in Novo Nordisk A/S (NYSE:NVO)

Whipplewood Advisors LLC acquired a new stake in shares of Novo Nordisk A/S (NYSE:NVO) in the fourth quarter, according to its most recent disclosure with the SEC. The firm acquired 5,987 shares of the company’s stock, valued at approximately $515,000.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Natixis Advisors LLC grew its stake in Novo Nordisk A/S by 2.7% during the third quarter. Natixis Advisors LLC now owns 3,074,876 shares of the company’s stock valued at $366,125,000 after acquiring an additional 80,070 shares in the last quarter. Norman Fields Gottscho Capital Management LLC boosted its holdings in shares of Novo Nordisk A/S by 45.3% during the 4th quarter. Norman Fields Gottscho Capital Management LLC now owns 63,732 shares of the company’s stock valued at $5,482,000 after purchasing an additional 19,870 shares during the last quarter. Bryn Mawr Capital Management LLC grew its position in shares of Novo Nordisk A/S by 358.8% during the fourth quarter. Bryn Mawr Capital Management LLC now owns 38,898 shares of the company’s stock valued at $3,346,000 after purchasing an additional 30,420 shares in the last quarter. Versant Capital Management Inc bought a new stake in shares of Novo Nordisk A/S in the fourth quarter worth about $86,000. Finally, Talbot Financial LLC purchased a new stake in shares of Novo Nordisk A/S in the fourth quarter worth about $4,066,000. Institutional investors own 11.54% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on NVO shares. StockNews.com cut Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Sunday, December 29th. UBS Group raised shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. BNP Paribas raised shares of Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. Morgan Stanley assumed coverage on shares of Novo Nordisk A/S in a research note on Wednesday, February 12th. They issued an “equal weight” rating for the company. Finally, Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. Two analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $145.25.

Novo Nordisk A/S Trading Down 1.4 %

NVO stock opened at $89.67 on Thursday. Novo Nordisk A/S has a twelve month low of $77.82 and a twelve month high of $148.15. The stock has a market capitalization of $402.41 billion, a price-to-earnings ratio of 27.26, a price-to-earnings-growth ratio of 0.90 and a beta of 0.45. The company has a quick ratio of 0.55, a current ratio of 0.74 and a debt-to-equity ratio of 0.62. The firm’s fifty day simple moving average is $84.99 and its two-hundred day simple moving average is $107.30.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings results on Wednesday, February 5th. The company reported $0.91 EPS for the quarter, beating the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. As a group, analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Increases Dividend

The firm also recently declared a semi-annual dividend, which will be paid on Tuesday, April 8th. Stockholders of record on Monday, March 31st will be issued a $0.7874 dividend. This represents a dividend yield of 1.2%. This is an increase from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. The ex-dividend date of this dividend is Monday, March 31st. Novo Nordisk A/S’s dividend payout ratio is presently 47.72%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.